Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Sicca Syndrome (Sjogren) Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Sicca Syndrome (Sjogren) Overview | 9 | 1 |
| Pipeline Products for Sicca Syndrome (Sjogren) Comparative Analysis | 10 | 1 |
| Sicca Syndrome (Sjogren) Therapeutics under Development by Companies | 11 | 1 |
| Sicca Syndrome (Sjogren) Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Sicca Syndrome (Sjogren) Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Sicca Syndrome (Sjogren) Products under Development by Companies | 16 | 1 |
| Sicca Syndrome (Sjogren) Products under Investigation by Universities/Institutes | 17 | 1 |
| Sicca Syndrome (Sjogren) Companies Involved in Therapeutics Development | 18 | 12 |
| Akari Therapeutics, Plc | 18 | 1 |
| Amgen Inc. | 19 | 1 |
| Ampio Pharmaceuticals, Inc. | 20 | 1 |
| Biogen, Inc. | 21 | 1 |
| Bristol-Myers Squibb Company | 22 | 1 |
| Eli Lilly and Company | 23 | 1 |
| F. Hoffmann-La Roche Ltd. | 24 | 1 |
| GlaxoSmithKline Plc | 25 | 1 |
| MedImmune, LLC | 26 | 1 |
| Redx Pharma Plc | 27 | 1 |
| Toleranzia AB | 28 | 1 |
| UCB S.A. | 29 | 1 |
| Sicca Syndrome (Sjogren) Therapeutics Assessment | 30 | 9 |
| Assessment by Monotherapy Products | 30 | 1 |
| Assessment by Target | 31 | 2 |
| Assessment by Mechanism of Action | 33 | 2 |
| Assessment by Route of Administration | 35 | 2 |
| Assessment by Molecule Type | 37 | 2 |
| Drug Profiles | 39 | 32 |
| abatacept - Drug Profile | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 4 |
| ABS-11 - Drug Profile | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 1 |
| AMG-557 - Drug Profile | 44 | 1 |
| Product Description | 44 | 1 |
| Mechanism of Action | 44 | 1 |
| R&D Progress | 44 | 2 |
| Ampion - Drug Profile | 46 | 1 |
| Product Description | 46 | 1 |
| Mechanism of Action | 46 | 1 |
| R&D Progress | 46 | 2 |
| belimumab - Drug Profile | 48 | 1 |
| Product Description | 48 | 1 |
| Mechanism of Action | 48 | 1 |
| R&D Progress | 48 | 4 |
| BIIB-063 - Drug Profile | 52 | 1 |
| Product Description | 52 | 1 |
| Mechanism of Action | 52 | 1 |
| R&D Progress | 52 | 1 |
| CDZ-173 - Drug Profile | 53 | 1 |
| Product Description | 53 | 1 |
| Mechanism of Action | 53 | 1 |
| R&D Progress | 53 | 1 |
| Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile | 54 | 1 |
| Product Description | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| R&D Progress | 54 | 1 |
| CFZ-533 - Drug Profile | 55 | 1 |
| Product Description | 55 | 1 |
| Mechanism of Action | 55 | 1 |
| R&D Progress | 55 | 2 |
| Coversin - Drug Profile | 57 | 1 |
| Product Description | 57 | 1 |
| Mechanism of Action | 57 | 1 |
| R&D Progress | 57 | 2 |
| GSK-2618960 - Drug Profile | 59 | 1 |
| Product Description | 59 | 1 |
| Mechanism of Action | 59 | 1 |
| R&D Progress | 59 | 1 |
| IMSO-001 - Drug Profile | 60 | 1 |
| Product Description | 60 | 1 |
| Mechanism of Action | 60 | 1 |
| R&D Progress | 60 | 1 |
| LY-3090106 - Drug Profile | 61 | 1 |
| Product Description | 61 | 1 |
| Mechanism of Action | 61 | 1 |
| R&D Progress | 61 | 1 |
| MEDI-4920 - Drug Profile | 62 | 1 |
| Product Description | 62 | 1 |
| Mechanism of Action | 62 | 1 |
| R&D Progress | 62 | 1 |
| MEDI-7734 - Drug Profile | 63 | 1 |
| Product Description | 63 | 1 |
| Mechanism of Action | 63 | 1 |
| R&D Progress | 63 | 1 |
| RDX-002 - Drug Profile | 64 | 1 |
| Product Description | 64 | 1 |
| Mechanism of Action | 64 | 1 |
| R&D Progress | 64 | 1 |
| Recombinant Protein for Sjogren's Syndrome - Drug Profile | 65 | 1 |
| Product Description | 65 | 1 |
| Mechanism of Action | 65 | 1 |
| R&D Progress | 65 | 1 |
| RG-7625 - Drug Profile | 66 | 1 |
| Product Description | 66 | 1 |
| Mechanism of Action | 66 | 1 |
| R&D Progress | 66 | 1 |
| seletalisib - Drug Profile | 67 | 1 |
| Product Description | 67 | 1 |
| Mechanism of Action | 67 | 1 |
| R&D Progress | 67 | 1 |
| VAY-736 - Drug Profile | 68 | 1 |
| Product Description | 68 | 1 |
| Mechanism of Action | 68 | 1 |
| R&D Progress | 68 | 2 |
| VM-200 - Drug Profile | 70 | 1 |
| Product Description | 70 | 1 |
| Mechanism of Action | 70 | 1 |
| R&D Progress | 70 | 1 |
| Sicca Syndrome (Sjogren) Recent Pipeline Updates | 71 | 18 |
| Sicca Syndrome (Sjogren) - Dormant Projects | 89 | 1 |
| Sicca Syndrome (Sjogren) Discontinued Products | 90 | 1 |
| Sicca Syndrome (Sjogren) Product Development Milestones | 91 | 1 |
| Featured News &Press Releases | 91 | 1 |
| Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren s syndrome | 91 | 1 |
| Appendix | 92 | 2 |
| Methodology | 92 | 1 |
| Coverage | 92 | 1 |
| Secondary Research | 92 | 1 |
| Primary Research | 92 | 1 |
| Expert Panel Validation | 92 | 1 |
| Contact Us | 92 | 1 |
| Disclaimer | 93 | 1 |